We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Touchlight announced the clinical supply of its proprietary dbDNA™ to the University of Nottingham for research and development of a next-generation DNA vaccine targeting the Zika virus.